CBD vs THC: What the Clinical Evidence Actually Shows

The CBD vs THC question is one of the most common in medical marijuana. Patients want to know: which one do I need? Is CBD enough, or do I need THC? What about using both together?

The answers depend on your condition, your symptoms, and your goals. But they also depend on evidence — and the clinical evidence for these two cannabinoids is more developed than most people realize. Here's what controlled studies, systematic reviews, and clinical trials actually show about when to use CBD, when to use THC, and when the combination outperforms either alone.

Different Molecules, Different Mechanisms

THC and CBD are both cannabinoids derived from the same plant, but they interact with your body through fundamentally different mechanisms:

THC (delta-9-tetrahydrocannabinol):

• Partial agonist at CB1 receptors (brain and central nervous system)
• Partial agonist at CB2 receptors (immune system)
• Produces psychoactive effects through CB1 activation
• Primary mechanisms: direct receptor binding, neurotransmitter modulation

CBD (cannabidiol):

• Low direct affinity for CB1 and CB2 receptors
• Negative allosteric modulator of CB1 (changes the receptor shape to reduce THC's binding efficiency)
• Inhibits FAAH enzyme (increases natural anandamide levels)
• Agonist at serotonin 5-HT1A receptors
• Agonist at TRPV1 vanilloid receptors
• Antagonist at GPR55 receptors
• Modulates glycine receptors (relevant to pain)
• Primary mechanisms: indirect modulation, multi-target pharmacology

This difference in mechanism means they're not just "stronger" and "weaker" versions of the same thing. They're genuinely different medicines that happen to come from the same plant.

Conditions Where THC Has Stronger Evidence

Chronic Pain (Especially Neuropathic)

THC is the more potent analgesic. Multiple randomized controlled trials have demonstrated THC's efficacy for chronic pain:

• Abrams et al. (2007) showed smoked medical marijuana (THC) reduced HIV-associated neuropathic pain by 34% vs 17% for placebo.
• Ware et al. (2010) demonstrated inhaled THC reduced chronic neuropathic pain intensity with concurrent sleep improvement.
• The 2017 National Academies of Sciences report concluded there was "conclusive or substantial evidence" that cannabinoids (primarily THC-containing products) are effective for chronic pain in adults.

CBD alone has much weaker evidence for pain. While CBD has anti-inflammatory properties that can help with inflammatory pain conditions, its direct analgesic effects are modest compared to THC. A 2020 systematic review by Argueta et al. in the Journal of Cannabis Research found that CBD-only products showed inconsistent results for pain, while THC-containing products showed more reliable effects.

Clinical implication: If your primary concern is pain relief, you likely need a product containing THC. CBD may complement THC's analgesic effects, but CBD alone is usually insufficient for moderate to severe pain.

Nausea and Vomiting

THC has well-established antiemetic (anti-nausea) properties. Dronabinol (synthetic THC) has been FDA-approved for chemotherapy-induced nausea and vomiting since 1985. CBD has not shown significant antiemetic effects in controlled studies.

A 2001 systematic review by Tramer et al. in the BMJ analyzed 30 randomized trials of cannabinoids for chemotherapy-induced nausea and found that cannabinoids (all THC-based) were more effective than conventional antiemetics available at the time.

Appetite Stimulation

THC increases appetite through CB1 receptor activation in the hypothalamus. This is well-documented and is the basis for dronabinol's second FDA-approved indication — appetite stimulation in AIDS-related wasting.

CBD does not stimulate appetite. In some studies, it may actually reduce appetite, though the evidence is inconsistent.

Clinical implication: For patients with cachexia, wasting, or poor appetite from any cause, THC is the relevant cannabinoid.

Muscle Spasticity

Nabiximols (Sativex) — a 1:1 THC:CBD spray — is approved in multiple countries for MS-related spasticity based on multiple Phase III trials. However, the THC component appears to be the primary driver:

• Wade et al. (2004) compared THC alone, CBD alone, and the 1:1 combination for MS symptoms. THC alone and the combination both showed benefit for spasticity; CBD alone did not.
• A 2012 Cochrane review concluded that THC-containing cannabinoids showed modest benefit for spasticity, while CBD alone had not demonstrated efficacy for this indication.

Conditions Where CBD Has Stronger Evidence

Epilepsy and Seizure Disorders

This is CBD's strongest evidence base — and it's not close. Epidiolex (pure pharmaceutical CBD) was approved by the FDA in 2018 based on rigorous randomized controlled trials:

• Devinsky et al. (2017) in the New England Journal of Medicine demonstrated that CBD reduced seizure frequency by 39% in patients with Dravet syndrome, compared to 13% with placebo.
• Thiele et al. (2018) in the New England Journal of Medicine showed similar results in Lennox-Gastaut syndrome — CBD reduced drop seizures by 42% vs 17% for placebo.

THC, by contrast, has not demonstrated consistent anti-seizure effects and may actually lower seizure threshold in some patients.

Clinical implication: For seizure disorders, CBD is the evidence-based choice. THC may be counterproductive.

Anxiety Disorders

CBD has the stronger evidence base for anxiety. Multiple studies show anxiolytic effects:

• Zuardi et al. (1993) showed that CBD reduced anxiety induced by simulated public speaking in healthy volunteers.
• Bergamaschi et al. (2011) in Neuropsychopharmacology conducted a randomized, double-blind study showing that 600mg of CBD significantly reduced anxiety, cognitive impairment, and discomfort in speech performance compared to placebo in patients with social anxiety disorder.
• A 2015 systematic review by Blessing et al. in Neurotherapeutics concluded that existing evidence "strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive-compulsive disorder, and post-traumatic stress disorder."

THC's relationship with anxiety is complicated. At low doses, THC can reduce anxiety. At higher doses or in anxiety-prone individuals, THC can increase anxiety and paranoia. This dose-dependent, biphasic relationship makes THC unreliable as a primary anxiolytic.

Clinical implication: For anxiety as a primary symptom, CBD is generally preferred. If THC is used (e.g., for co-occurring pain), combining it with CBD can mitigate THC-induced anxiety.

Psychosis and Schizophrenia

CBD has emerging evidence as an antipsychotic. McGuire et al. (2018) in the American Journal of Psychiatry conducted a randomized controlled trial showing that 1000mg/day of CBD significantly reduced psychotic symptoms in schizophrenia patients compared to placebo, with fewer side effects than conventional antipsychotics.

THC, conversely, can worsen psychotic symptoms and is a risk factor for psychotic episodes in vulnerable individuals. Morrison et al. (2009) showed that IV THC increased psychotic symptoms in healthy volunteers, while CBD was protective.

Clinical implication: Patients with a personal or family history of psychotic disorders should generally avoid high-THC products. CBD may actually be beneficial for this population.

The Power of Combination: Ratio Studies

Some of the most interesting clinical evidence involves specific THC:CBD ratios. The interaction between these cannabinoids creates effects that neither achieves alone.

1:1 THC:CBD

The most studied ratio, primarily through nabiximols (Sativex):

• Johnson et al. (2010) in the Journal of Pain and Symptom Management compared THC alone, 1:1 THC:CBD, and placebo in cancer pain patients already on opioids. The 1:1 combination was significantly better than placebo for pain relief; THC alone was not. This suggests CBD enhanced THC's analgesic effect — or that the combination achieved something neither did alone.
• Rog et al. (2005) showed that 1:1 THC:CBD reduced central neuropathic pain in MS patients more effectively than either would be expected to do alone based on individual-compound data.

The 1:1 ratio is also associated with fewer side effects than THC alone, because CBD's negative allosteric modulation of CB1 receptors dampens THC's tendency to cause anxiety, paranoia, and excessive intoxication.

High CBD:Low THC (e.g., 20:1, 10:1)

These ratios are commonly used for patients who want minimal psychoactivity:

• Pamplona et al. (2018) in Frontiers in Neurology analyzed 11 studies of CBD-rich medical cannabis extracts for epilepsy and found that CBD-rich extracts (which contain small amounts of THC and other cannabinoids) were effective at lower doses and with fewer side effects than purified CBD — suggesting that even small amounts of THC enhance CBD's therapeutic effects.
• For anxiety, a CBD-dominant ratio allows patients to get CBD's anxiolytic benefits with a small amount of THC that may enhance the entourage effect without producing significant intoxication.

High THC:Low CBD (e.g., 10:1 THC:CBD)

For patients who need THC's analgesic or antiemetic effects but want some CBD modulation:

• Adding even a small amount of CBD to a THC-dominant product may reduce the risk of THC-induced anxiety and cognitive impairment. Englund et al. (2013) in Journal of Psychopharmacology showed that CBD pretreatment reduced THC-induced paranoia and memory impairment.

A Decision Framework

Based on the clinical evidence, here's how Dr. Kim at CORAL approaches product recommendations:

| Primary Concern | Recommended Approach | Evidence Level |

|---|---|---|

| Chronic neuropathic pain | THC-dominant or 1:1 THC:CBD | Strong (multiple RCTs) |

| Inflammatory pain | 1:1 or CBD-dominant with some THC | Moderate |

| Nausea/vomiting | THC-dominant | Strong (FDA-approved) |

| Appetite loss | THC-dominant | Strong (FDA-approved) |

| Muscle spasticity | 1:1 THC:CBD or THC-dominant | Strong (multiple RCTs) |

| Seizure disorders | CBD-dominant (minimal THC) | Strong (FDA-approved) |

| Anxiety (primary) | CBD-dominant | Moderate-strong |

| PTSD | Balanced or THC-dominant | Moderate |

| Insomnia | THC or balanced | Moderate |

| General inflammation | CBD-dominant or balanced | Moderate |

This is a starting framework, not a rigid protocol. Individual response varies, and many patients benefit from adjusting their approach over time based on their experience.

What the Evidence Doesn't Support

To keep this evidence-based, several common claims deserve pushback:

"CBD does everything THC does, without the high." This is not supported by evidence. CBD and THC have distinct and often non-overlapping therapeutic profiles. For pain, nausea, appetite, and spasticity, THC is clearly more effective.

"THC is recreational, CBD is medical." Both are medical when used appropriately. THC has more FDA-approved medical indications (dronabinol, nabilone) than CBD (Epidiolex). The distinction between "recreational" and "medical" is about context and intent, not about the molecule.

"Higher THC percentage means better medicine." The evidence consistently shows that moderate doses of THC are more effective than high doses for most conditions. Higher THC percentages require more careful dosing, not less, and are associated with more side effects without proportionally greater benefit.

"CBD is completely safe with no side effects." CBD is generally well-tolerated, but it's not without effects. It interacts with cytochrome P450 enzymes and can alter blood levels of other medications (particularly anti-epileptic drugs, blood thinners, and immunosuppressants). At higher doses, it can cause drowsiness, diarrhea, and reduced appetite.

The Bottom Line

The clinical evidence shows that THC and CBD are complementary but distinct medicines. Neither is universally better. The right choice depends on your condition, your symptoms, your other medications, and your individual response.

The strongest approach for most medical marijuana patients is a thoughtful combination — using the ratio and dose that matches your clinical needs, then adjusting based on response. That's the approach Dr. Kim takes at CORAL: evidence-informed, individually tailored, and grounded in what the research actually shows.

---

Want guidance on which cannabinoid profile is right for your condition? Start your evaluation at [coral.clinic/start](https://coral.clinic/start).